RE:RE:RE:RE:RE:EY sees bolt-ons in the single to double digit billions now Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC)
Successful phase III oncology trials are more likely to employ biomarker-driven patient selection https://jitc.bmj.com/content/10/9/e005413?utm_source=other-external-site&utm_medium=referral&utm_campaign=usage&utm_content=americas-society&utm_term=jitc